Novartis Rhapsido FDA Approval: Remibrutinib Becomes First Treatment for Symptomatic Dermographism

The Novartis Rhapsido FDA approval, announced on October 7, 2026, makes remibrutinib the first approved treatment for adults with symptomatic dermographism (SD) whose symptoms are inadequately controlled by H1 antihistamines. Novartis announced the decision from Basel, expanding Rhapsido beyond chronic spontaneous urticaria (CSU). The company says the milestone matters for people whose chronic hives and itch can be triggered by everyday skin friction, scratching, or rubbing.

Rhapsido (remibrutinib) is an oral, highly selective Bruton’s tyrosine kinase inhibitor (BTKi). According to Novartis, it blocks the BTK pathway involved in the release of histamine, a key driver of hives (wheals) and swelling. The U.S. Food and Drug Administration decision covers adults with SD, while Rhapsido already carried a U.S. indication in CSU. Novartis frames the news as part of the potential of BTK inhibition across immune-mediated diseases.

For readers following chronic urticaria coverage, the Novartis Rhapsido FDA approval matters because SD has historically had limited treatment options. Novartis states that SD is the most prevalent type of chronic inducible urticaria (CIndU), and that more than 50% of patients remain symptomatic despite taking H1 antihistamines. The company also reports that over 90% of adults with chronic hives experience either CSU or SD, which places this indication in the middle of the chronic hives population.

Novartis Rhapsido FDA Approval: What the RemIND Phase III Data Show

The approval rests on the SD cohort of the Phase III RemIND clinical trial, which included patients who remained symptomatic on second-generation H1 antihistamines. Efficacy was measured as complete response from hives using the Total Fric Score. Novartis did not disclose enrollment numbers for the SD cohort in the release, so none are reported here.

Learn More

Johnson & Johnson CAPLYTA Bipolar Mania Study Shows Significant and Rapid Improvement

At Week 12, 29.3% of patients treated with Rhapsido achieved complete response from hives, compared with 14.0% on placebo (p=0.0229). Novartis said responses were seen as early as Week 2. In its summary, the company stated that twice as many adults taking Rhapsido reached complete hive resolution by Week 12 versus placebo, a difference that was statistically significant according to the release.

In clinical trials up to Week 24, Rhapsido showed a safety profile in SD consistent with CSU. The most common adverse events, at an incidence of 3% or higher, were nasal congestion, sore throat and runny nose (nasopharyngitis), bleeding, headache, nausea and abdominal pain. Novartis adds that no routine laboratory monitoring is required, a practical point it emphasizes alongside the Novartis Rhapsido FDA approval.

Why the Novartis Rhapsido FDA Approval Expands Options Beyond CSU

With this decision, Rhapsido is now the only treatment indicated for the two most common forms of chronic hives, CSU and SD, according to Novartis. The company says it is the only prescription treatment with approved uses in both conditions when antihistamines alone do not control symptoms. The first U.S. indication, in CSU, came just over a year before the SD decision.

Victor Bultó, President, US at Novartis, said the approval builds on that CSU milestone and could help more people find relief from persistent itch. Giselle Mosnaim, MD, an allergist and lead RemIND investigator, described the result as “a meaningful step forward” for this population. Lindsey Finklea, MD, a dermatologist and RemIND investigator, said it changes how clinicians can approach care.

Kristen Willard, Executive Director of We CU, a global community supporting people with chronic urticaria, said the approval of remibrutinib represents important progress for the SD community. She added that patients deserve treatment options developed specifically for their condition. The release presents her comments from both a patient and an advocacy perspective.

Learn More

Novo HRS-1596 License: Novo Secures Hengrui Pharma’s Oral Once-Weekly GLP-1/GIP Agonist in Deal Worth Up to $2.6 Billion

Novartis Rhapsido FDA Approval and the Wider Remibrutinib Pipeline

Beyond SD, the RemIND study also evaluated remibrutinib in other forms of CIndU, including cold urticaria (ColdU) and cholinergic urticaria (CholU). Novartis plans to submit the full RemIND dataset to health authorities globally, where appropriate. The timing of those submissions was not disclosed in the release.

Remibrutinib continues to be studied in hidradenitis suppurativa (HS), food allergy and multiple sclerosis (MS). Novartis recently announced positive topline Phase III REMODEL-1/-2 results in relapsing multiple sclerosis (RMS), reporting a clinically meaningful reduction in annualized relapse rates and a clinically meaningful delay in disability progression versus teriflunomide. The company also reported no liver safety signals.

Outside the U.S., Rhapsido is approved in the EU, UK and China for adults with CSU inadequately controlled by H1 antihistamines. The Novartis Rhapsido FDA approval is the only SD indication listed in the release, so the SD approval appears limited to the U.S. at this stage.

What the Novartis Rhapsido FDA Approval Means for Patients and Clinicians

For patients whose hives are triggered by skin contact and who remain symptomatic on H1 antihistamines, the Novartis Rhapsido FDA approval offers a treatment specifically indicated for SD. Pricing, U.S. launch timing and availability were not disclosed in the release. Clinicians should rely on the full Rhapsido prescribing information, which Novartis cites as the source for its efficacy and safety claims.

The release contains forward-looking statements, including expectations about future regulatory submissions and potential new indications. Novartis cautions that there is no guarantee any product will be submitted or approved for additional indications, and it points readers to its SEC filings for risk factors. In short, the Novartis Rhapsido FDA approval gives SD patients and clinicians a first FDA-approved option, and further data will determine its broader role.

Table 1: Approval Snapshot

Table 2: RemIND Phase III Efficacy (SD Cohort)

Table 3: Disease Context and Safety

Table 4: Regulatory Status and Pipeline